Ethical concerns regarding heterologous COVID-19 vaccine administration

Ethical concerns regarding heterologous COVID-19 vaccine administration

Saved in:

Bibliographic Details
Main Authors:	Somsri Wiwanitkit, Viroj Wiwanitkit
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	Covid vaccine ethic heterologous
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2313250
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination
by: Somsri Wiwanitkit, et al.
Published: (2023-12-01)

Humoral response against spike protein and fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects: What should be for the seventh dose?
by: Somsri Wiwanitkit, et al.
Published: (2023-12-01)

Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine
by: Sora Yasri, et al.
Published: (2024-08-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
by: Jianyang Liu, et al.
Published: (2023-12-01)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
by: Qian He, et al.
Published: (2021-01-01)

Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine
by: Zhifei Chen, et al.
Published: (2025-01-01)

Comparison of homologous and heterologous vaccination strategies for combating disease caused by Burkholderia pseudomallei
by: Sergei S. Biryukov, et al.
Published: (2025-06-01)

Microneedle Delivery of Heterologous Microparticulate COVID-19 Vaccine Induces Cross Strain Specific Antibody Levels in Mice
by: Tanisha Manoj Arte, et al.
Published: (2025-04-01)

Politics and confidence toward the COVID-19 vaccination: Points to be considered
by: Somsri Wiwanitkit, et al.
Published: (2024-12-01)

How Much Protection can COVID-19 Vaccine Give Compared to No Vaccination? A Reappraisal
by: Somsri Wiwanitkit, et al.
Published: (2024-01-01)

Comment on “Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis”
by: Amin Sharifan
Published: (2024-12-01)

Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants
by: Ji Hyang Jeon, et al.
Published: (2025-05-01)

Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination
by: Davide Torre, et al.
Published: (2025-05-01)

Immune mechanisms mediating the heterologous effects of BCG vaccination: a systematic review
by: Louis Torracinta, et al.
Published: (2025-05-01)

RSV awareness, risk perception, causes, and terms: Comment
by: Somsri Wiwanitkit, et al.
Published: (2023-12-01)

Heterologous prime–boost Zika virus vaccination induces comprehensive humoral and cellular immunity in mouse models
by: Giuditta De Lorenzo, et al.
Published: (2025-04-01)

Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine
by: Dandan Peng, et al.
Published: (2023-04-01)

A goatpox but not sheeppox heterologous live attenuated vaccines provide complete protection against lumpy skin disease in cattle under experimental conditions
by: Andy Haegeman, et al.
Published: (2025-07-01)

Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization
by: William R. Lykins, et al.
Published: (2024-12-01)

Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response
by: Ali Toloue Ostadgavahi, et al.
Published: (2021-05-01)

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
by: Jialu Zhang, et al.
Published: (2021-01-01)

Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial
by: Bei-Fang Yang, et al.
Published: (2025-12-01)

Decade-Long Sustained Cellular Immunity Induced by Sequential and Repeated Vaccination with Four Heterologous HIV Vaccines in Rhesus Macaques
by: Xiaozhou He, et al.
Published: (2025-03-01)

Intraneural ganglion cyst of the peroneal nerve and coronavirus disease-19 vaccination: Relationship and possible mechanism
by: Somsri Wiwanitkit, et al.
Published: (2023-12-01)

PRRSV GP4 subunit vaccine combined with adenovirus heterologous prime-boost immunization strategy induced a significant immune response in mice
by: Honghuan Li, et al.
Published: (2025-05-01)

Addressing vaccine hesitancy, rebuilding trust and addressing health disparities among racial and ethnic minority communities: Comment
by: Amnuay Kleebayoon, et al.
Published: (2024-12-01)

Regarding “Reply to the enhancing the accuracy of seroprevalence studies: Reassessing pertussis infection rates in Eastern China during the COVID-19 pandemic”
by: Hinpetch Daungsupawong, et al.
Published: (2024-12-01)

Heterologous Expression and Transglycosylation of Acarviosyltransferase
by: XUE Zhenglian, WANG Yuqing, LI Chuang, LI Dandan, ZHU Sibao, LI Xiangfei
Published: (2025-01-01)

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
by: Lairun Jin, et al.
Published: (2023-12-01)

Professional ethics of recommendations: implications for COVID-19 vaccination of women who are pregnant or planning to become pregnant
by: F. A. Chervenak, et al.
Published: (2021-12-01)

A SWOT Analysis of COVID-19 Human Challenge Trials in Light of Christian Ethics: Is Infecting Healthy Humans with Coronavirus in Order to develop vaccines ethical?
by: Daniel Lagat
Published: (2023-06-01)

Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination
by: Nungruthai Suntronwong, et al.
Published: (2023-12-01)

Effect of Homologous and Heterologous Booster in COVID-19 Vaccination
by: Marija Vukčević, et al.
Published: (2024-12-01)

Editorial: Ethics and Teacher Vaccinations during COVID-19
by: Christoph Teschers, et al.
Published: (2021-12-01)

Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
by: Jialu Zhang, et al.
Published: (2022-12-01)

COVID-19 vaccination and concerns regarding vaccine hesitancy after the termination of the zero-COVID policy in China: A nationwide cross-sectional study
by: Min Yang, et al.
Published: (2024-12-01)

Improving the Properties of Laccase Through Heterologous Expression and Protein Engineering
by: Guoqiang Guan, et al.
Published: (2025-06-01)

Distinct humoral responses induced by heterologous versus homologous prime–boost immunization strategies in early life
by: Poorya Foroutan Pajoohian, et al.
Published: (2025-08-01)

Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study
by: Nayab Batool Rizvi, et al.
Published: (2024-11-01)